Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -8.31% is 75% above its 5-year average of -32.91%, near the high end of its 5-year range (-75.17%–-4.37%).
13.62% above its 12-month average of -9.62%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -8.58%.
OPERATING MARGIN
-8.31%
OPERATING MARGIN AVG TTM
-9.62%
OPERATING MARGIN AVG 3Y
-19.39%
OPERATING MARGIN AVG 5Y
-32.91%
OPERATING MARGIN AVG 10Y
-37.29%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.62%
CURRENT VS 3Y AVG
+57.13%
CURRENT VS 5Y AVG
+74.75%
CURRENT VS 10Y AVG
+77.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
SI-BONE, Inc.
Market Cap
$859.52M
Operating Margin
-8.31%
TTM Avg
-9.62%
3Y Avg
-19.39%
5Y Avg
-32.91%
Market Cap
$857.94M
Operating Margin
42.63%
TTM Avg
28.06%
3Y Avg
-1.90%
5Y Avg
-7.11%
Market Cap
$855.16M
Operating Margin
-174.65%
TTM Avg
-105.11%
3Y Avg
-66.40%
5Y Avg
-66.40%
Market Cap
$865.24M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$845.02M
Operating Margin
-30.67%
TTM Avg
-52.06%
3Y Avg
-18.41%
5Y Avg
7.25%
Market Cap
$842.48M
Operating Margin
-348.46%
TTM Avg
-328.22%
3Y Avg
-265.67%
5Y Avg
-226.03%
Market Cap
$877.07M
Operating Margin
-192.08%
TTM Avg
-714.41%
3Y Avg
-506.77%
5Y Avg
-588.71%
Market Cap
$836.24M
Operating Margin
-43.83%
TTM Avg
-75.55%
3Y Avg
-37.77%
5Y Avg
-25.18%
Market Cap
$834.16M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $859.52M | -8.31% | -9.62% | -19.39% | -32.91% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $857.94M | 42.63% | 28.06% | -1.90% | -7.11% |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | -174.65% | -105.11% | -66.40% | -66.40% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| QuidelOrtho Corporation (QDEL)vs › | $845.02M | -30.67% | -52.06% | -18.41% | 7.25% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $842.48M | -348.46% | -328.22% | -265.67% | -226.03% |
| Arbutus Biopharma Corp (ABUS)vs › | $877.07M | -192.08% | -714.41% | -506.77% | -588.71% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.24M | -43.83% | -75.55% | -37.77% | -25.18% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $834.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| Beta Bionics, Inc. (BBNX)vs › | $833.88M | -69.75% | -70.49% | -9306.05% | -9306.05% |
Gross Margin
79.5%
Operating Margin
-8.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -8.58% |
| 2026-03-31 | -9.68% |
| 2025-12-31 | -4.37% |
| 2025-09-30 | -11.06% |
| 2025-06-30 | -14.40% |
| 2025-03-31 | -15.82% |
| 2024-12-31 | -11.21% |
| 2024-09-30 | -18.92% |
| 2024-06-30 | -25.21% |
| 2024-03-31 | -31.80% |
| 2023-12-31 | -32.18% |
| 2023-09-30 | -32.84% |
| 2023-06-30 | -35.92% |
| 2023-03-31 | -34.53% |
| 2022-12-31 | -35.35% |
| 2022-09-30 | -51.32% |
| 2022-06-30 | -69.89% |
| 2022-03-31 | -75.17% |
| 2021-12-31 | -55.22% |
| 2021-09-30 | -59.23% |
| 2021-06-30 | -58.42% |
| 2021-03-31 | -56.62% |
| 2020-12-31 | -35.54% |
| 2020-09-30 | -42.58% |
| 2020-06-30 | -72.17% |
| 2020-03-31 | -70.64% |
| 2019-12-31 | -42.83% |
| 2019-09-30 | -65.39% |
| 2019-06-30 | -49.87% |
| 2019-03-31 | -58.70% |
| 2018-12-31 | -27.57% |
| 2018-09-30 | -22.75% |
| 2018-06-30 | -12.42% |
| 2018-03-31 | -22.95% |
| 2017-12-31 | -11.92% |
| 2017-09-30 | -43.13% |
| 2017-06-30 | -42.13% |
| 2017-03-31 | -48.62% |
| 2016-03-31 | -67.60% |
| 2015-03-31 | -66.41% |
| 2014-12-31 | -73.41% |
| 2014-03-31 | -33.18% |
